FibroScan受控衰减参数对非酒精性脂肪性肝病的诊断效能及与中医证型的相关性分析

刘建鹏; 于中杰; 王晗笑; 赵文霞

doi:10.3969/j.issn.1001-5256.2021.12.026

FibroScan受控衰减参数对非酒精性脂肪性肝病的诊断效能及与中医证型的相关性分析

DOI: 10.3969/j.issn.1001-5256.2021.12.026

1.
河南中医药大学第一临床医学院, 郑州 450000
2.
河南中医药大学第一附属医院脾胃肝胆科, 郑州 450000

基金项目:

河南省中医药科学研究专项重点课题 (2014ZY01012);

河南省中医药科学研究专项 (2018JDZX005)

详细信息

通信作者:
赵文霞, zhao-wenxia@163.com

中图分类号: R575.5
计量
- 文章访问数: 464
- HTML全文浏览量: 229
- PDF下载量: 32
- 被引次数: 0
出版历程
- 收稿日期: 2021-04-29
- 录用日期: 2021-05-21
- 出版日期: 2021-12-20

Performance of controlled attenuation parameter measured by FibroScan in the diagnosis of nonalcoholic fatty liver disease and its association with traditional Chinese medicine syndrome types

1.
The First Clinical Medical College, Henan University of Chinese Medicine, Zhengzhou 450000, China
2.
Department of Hepatology and Spleen-Stomach, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China

Research funding:

Special Key Project of Henan Province Traditional Chinese Medicine Scientific Research (2014ZY01012);

Research on the Optimal Treatment of Non-alcoholic Steatohepatitis Based on the Combination of Disease and Syndrome (2018JDZX005)

摘要

摘要: 目的探讨FibroScan检测肝脂肪变受控衰减参数(CAP)在非酒精性脂肪性肝病(NAFLD)的诊断及在中医辨证分型中的应用价值。方法回顾性收集2017年1月—2019年12月于河南中医药大学第一附属医院就诊的364例NAFLD患者的基本信息(年龄、性别、BMI)、FibroScan CAP值、肝胆脾胰超声检查结果以及肝功能、血脂指标, 根据中医辨证分型分为肝郁脾虚证组、湿浊内停证组、湿热蕴结证组、痰瘀互结证组和脾肾两虚证组, 分析CAP值、彩超、肝功能指标、血脂指标、BMI与中医证型之间的关系。符合正态分布的计量资料多组间比较采用单因素方差分析, 进一步两两比较采用LSD-t检验; 不符合正态分布的计量资料多组间及进一步两组间比较采用多个独立样本Kruskal-Wallis H秩和检验。计数资料多组间及进一步两组间比较采用χ²检验或Kruskal-Wallis H检验。采用Spearman秩相关分析CAP值与超声分级的相关性。结果 364例NAFLD患者中, 肝郁脾虚证169例, 湿浊内停证71例, 湿热蕴结证60例, 痰瘀互结证41例, 脾肾两虚证23例。不同证型之间CAP值差异有统计学意义(F=14.839, P＜0.001), 脾肾两虚证、痰瘀互结证与肝郁脾虚证、湿浊内停证、湿热蕴结证相比CAP值升高更明显(P值均＜0.05);不同证型超声分级差异有统计学意义(χ²=22.947, P＜0.001), 其中肝郁脾虚证以轻度为主(40.2%), 湿浊内停证和湿热蕴结证以中度为主(53.5%、53.3%), 痰瘀互结证、脾肾两虚证以重度为主(68.3%、43.5%); CAP值与脂肪肝严重程度呈正相关(r=0.431, P＜0.001);脾肾两虚证和痰瘀互结证患者ALT、AST、GGT和BMI水平与其他3个证型患者相比升高更明显(P值均＜0.001)。结论 CAP与NAFLD中医证型之间存在关联性, 痰瘀互结证与脾肾两虚证NAFLD患者CAP值相较于其他证型更高。CAP与彩超相比诊断NAFLD的效能相似。
- 非酒精性脂肪性肝病 /
- 弹性成像技术 /
- 受控衰减参数 /
- 诊断 /
- 证候 /
- 中医学
Abstract: Objective To investigate the application value of controlled attenuation parameter (CAP) of hepatocyte steatosis measured by FibroScan in the diagnosis and traditional Chinese medicine (TCM) syndrome differentiation of nonalcoholic fatty liver disease (NAFLD). Methods A retrospective analysis was performed for related data of 364 patients with NAFLD who attended The First Affiliated Hospital of Henan University of Traditional Chinese Medicine from January 2017 to December 2019, including basic information (age, sex, and body mass index [BMI]), CAP measured by FibroScan, ultrasound findings of the liver, gallbladder, spleen, and pancreas, liver function parameters, and blood lipid parameters. TCM syndrome differentiation was performed based on the information obtained by four diagnostic methods, and then the patients were divided into liver depression and spleen deficiency group, damp turbidity and stagnation group, damp-heat accumulation group, intermingled phlegm and blood stasis group, and spleen-kidney deficiency group. The association of CAP, color Doppler ultrasound findings, liver function parameters, blood lipid parameters, and BMI with TCM syndrome was analyzed. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; the Kruskal-Wallis H rank sum test with multiple sets of independent samples was used for comparison of non-normally distributed continuous data between multiple groups and further comparison between two groups. The chi-square test or Kruskal-Wallis H rank sum test was used for comparison of categorical data between multiple groups and further comparison between two groups. A Spearman's rank correlation analysis was used to investigate the correlation between CAP and ultrasound grading. Results Among the 364 patients with NAFLD, 169 had the syndrome of liver depression and spleen deficiency, 71 had the syndrome of damp turbidity and stagnation, 60 had the syndrome of damp-heat accumulation, 41 had the syndrome of intermingled phlegm and blood stasis, and 23 had the syndrome of spleen-kidney deficiency. There was a significant difference in CAP value between the different syndrome types (F=14.839, P < 0.001), and further comparison between two groups showed that the spleen-kidney deficiency group and the intermingled phlegm and blood stasis group had a significantly higher CAP value than the liver depression and spleen deficiency group, the damp turbidity and stagnation group, and the damp-heat accumulation group (all P < 0.05). There was a significant difference in ultrasound grading between the different syndrome types (χ²=22.947, P < 0.001); the liver depression and spleen deficiency group mainly had a mild grade (40.2%), the damp turbidity and stagnation group and the damp-heat accumulation group mainly had a moderate grade (53.5% and 53.3%, respectively), and the intermingled phlegm and blood stasis group and the spleen-kidney deficiency group mainly had a severe grade (68.3% and 43.5%, respectively). CAP was positively correlated with the severity of fatty liver (r=0.431, P < 0.001). The spleen-kidney deficiency group and the intermingled phlegm and blood stasis group had significantly higher levels of alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, and BMI than the other three groups (all P < 0.001). Conclusion Association is observed between CAP and the TCM syndrome types of NAFLD, and patients with the syndrome of spleen-kidney deficiency and the syndrome of intermingled phlegm and blood stasis have a higher CAP value than those with the other syndrome types. CAP has similar efficiency to color Doppler ultrasound in the diagnosis of NAFLD.
- Non-alcoholic Fatty Liver Disease /
- Elasticity Imaging Techniques /
- Controlled Attenuation Parameters /
- Diagnosis /
- Symptom Complex /
- TCM Science

HTML全文

表 1 不同证型NAFLD患者一般资料比较

组别	例数	男/女(例)	年龄(岁)
肝郁脾虚证	169	125/44	41.73±13.12
湿浊内停证	71	44/27	41.72±9.24
湿热蕴结证	60	49/11	44.15±7.38
痰瘀互结证	41	29/12	41.41±13.11
脾肾两虚证	23	19/4	37.09±14.52
统计值		χ²=7.945	F=1.537
P值		0.094	0.191

下载: 导出CSV

表 2 不同证型NAFLD患者CAP值比较

组别	例数	CAP(dB/m)
肝郁脾虚证	169	290.89±42.200
湿浊内停证	71	310.39±39.273¹⁾
湿热蕴结证	60	308.20±40.076¹⁾
痰瘀互结证	41	334.00±36.151¹⁾²⁾³⁾
脾肾两虚证	23	337.26±29.005¹⁾²⁾³⁾
F值		14.389
P值		＜0.001
注：与肝郁脾虚证比较，1)P＜0.05;与湿浊内停证比较，2)P＜0.05;与湿热蕴结证比较，3)P＜0.05。

下载: 导出CSV

表 3 不同证型NAFLD患者超声分级比较

组别	例数	超声分级[例(%)]
组别	例数	轻度	中度	重度
肝郁脾虚证	169	68(40.2)	46(27.2)	55(32.5)
湿浊内停证	71	10(14.1)	38(53.5)	23(32.4)
湿热蕴结证	60	8(13.3)	32(53.3)	20(33.3)
痰瘀互结证	41	6(14.6)	7(17.1)	28(68.3)
脾肾两虚证	23	4(17.4)	9(39.1)	10(43.5)

下载: 导出CSV

表 4 不同证型NAFLD患者肝功能、血脂、BMI指标水平比较

项目	肝郁脾虚证(n=169)	湿浊内停证(n=71)	湿热蕴结证(n=60)	痰瘀互结证(n=41)	脾肾两虚证(n=23)	统计值	P值
ALT(U/L)	35.20(22.75~55.40)	37.20(24.10~62.00)	34.05(21.85~50.87)	40.10(24.50~68.80)¹⁾²⁾³⁾	78.00(51.80~90.60)¹⁾²⁾³⁾	χ²=24.182	＜0.001
AST(U/L)	29.70(21.90~39.70)	29.90(21.00~49.9)	27.60(21.80~39.05)	67.20(57.75~79.85)¹⁾²⁾³⁾	78.00(45.10~82.10)¹⁾²⁾³⁾	χ²=89.031	＜0.001
GGT(U/L)	34.10(23.60~45.00)	40.90(21.70~79.90)	41.20(28.87~63.17)	45.00(32.65~87.55)¹⁾²⁾³⁾	45.00(25.40~58.80)¹⁾²⁾³⁾	χ²=20.616	＜0.001
TG(mmol/L)	1.86(1.50~2.18)	1.90(1.33~2.47)	2.56(1.92~4.12)¹⁾²⁾	3.10(2.22~3.87)^1)2)3)4)	2.10(1.77~2.81)¹⁾²⁾	χ²=67.445	＜0.001
BMI(kg/L²)	27.10±2.18	29.84±1.87	29.65±1.81	31.39±2.95¹⁾²⁾³⁾	30.77±4.67¹⁾²⁾³⁾	F=42.080	＜0.001
注: 与肝郁脾虚证比较，1)P＜0.05;与湿浊内停证比较，2)P＜0.05;与湿热蕴结证比较，3)P＜0.05;与脾肾两虚证比较，4)P＜0.05。

下载: 导出CSV

参考文献(17)

[1]	XUE R, FAN JG. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007. 薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.
[2]	Branch of Gastrointestinal Diseases, China Association of Chinese Medicine. Expert consensus on TCM diagnosis and treatment of nonalcoholic fatty liver disease (2017)[J]. J Clin Hepatol, 2017, 33(12): 2270-2274. DOI: 10.3969/j.issn.1001-5256.2017.12.002. 中华中医药学会脾胃病分会. 非酒精性脂肪性肝病中医诊疗专家共识意见(2017)[J]. 临床肝胆病杂志, 2017, 33(12): 2270-2274. DOI: 10.3969/j.issn.1001-5256.2017.12.002.
[3]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[4]	CHEN JN, CHEN AP, PAN Q, et al. Influential factors and clinical value of controlled attenuation parameters in the evaluation of hepatic steatosis using FibroScan^®[J]. Chin Hepatol, 2016, 21(10): 805-809. DOI: 10.3969/j.issn.1008-1704.2016.10.001. 陈建能, 陈爱萍, 潘勤, 等. FibroScan^®实施受控衰减参数检测肝脂肪变的影响因素及应用价值分析[J]. 肝脏, 2016, 21(10): 805-809. DOI: 10.3969/j.issn.1008-1704.2016.10.001.
[5]	CHEN GY, PAN Q, SHEN F, et al. Reproducibility study of Fibroscan for liver controlled attenuator parameters measurement[J]. Chin Hepatol, 2015, 20(11): 855-857. DOI: 10.3969/j.issn.1008-1704.2015.11.005. 陈光榆, 潘勤, 沈峰, 等. Fibroscan检测肝脏受控衰减参数的重复性研究[J]. 肝脏, 2015, 20(11): 855-857. DOI: 10.3969/j.issn.1008-1704.2015.11.005.
[6]	de LÉDINGHEN V, VERGNIOL J, CAPDEPONT M, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations[J]. J Hepatol, 2014, 60(5): 1026-1031. DOI: 10.1016/j.jhep.2013.12.018.
[7]	PU K, WANG Y, BAI S, et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. BMC Gastroenterol, 2019, 19(1): 51. DOI: 10.1186/s12876-019-0961-9.
[8]	ANDRADE P, RODRIGUES S, RODRIGUES-PINTO E, et al. Diagnostic accuracy of controlled attenuation parameter for detecting hepatic steatosis in patients with chronic liver disease[J]. GE Port J Gastroenterol, 2017, 24(4): 161-168. DOI: 10.1159/000453364.
[9]	TONG GD, XING YF, ZHOU XL, et al. Diagnosis and treatment scheme of Ganpi (non-alcoholic steatohepatitis)[J/CD]. Chin J Liver Dis(Electronic Edition), 2021, 13(1): 1-9. DOI: 10.3969/j.issn.1674-7380.2021.01.001. 童光东, 邢宇锋, 周晓玲, 等. 肝癖(非酒精性脂肪性肝炎)诊疗方案[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(1): 1-9. DOI: 10.3969/j.issn.1674-7380.2021.01.001.
[10]	MA YN, LIU JC. Research progress in the noninvasive quantitative diagnosis of hepatic steatosis using controlled attenuation parameters[J]. Chin J Gastroenterol Hepatol, 2020, 29(11): 1309-1312, 1316. DOI: 10.3969/j.issn.1006-5709.2020.11.023. 马亚楠, 刘近春. 受控衰减参数无创定量诊断肝脂肪变性的研究进展[J]. 胃肠病学和肝病学杂志, 2020, 29(11): 1309-1312, 1316. DOI: 10.3969/j.issn.1006-5709.2020.11.023.
[11]	VUPPALANCHI R, SIDDIQUI MS, van NATTA ML, et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease[J]. Hepatology, 2018, 67(1): 134-144. DOI: 10.1002/hep.29489.
[12]	KARLAS T, PETROFF D, SASSO M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis[J]. J Hepatol, 2017, 66(5): 1022-1030. DOI: 10.1016/j.jhep.2016.12.022.
[13]	WANG YH, ZHANG HO. Clinical research on evaluating nonalcoholic fatty liver and its TCM syndrome type by fat attenuation index[J]. Chin J Integr Tradit West Med Liver Dis, 2017, 27(1): 16-19. DOI: 10.3969/j.issn.1005-0264.2017.01.006. 王玉衡, 张海鸥. 应用脂肪衰减参数评价非酒精性脂肪肝与中医证型关系[J]. 中西医结合肝病杂志, 2017, 27(1): 16-19. DOI: 10.3969/j.issn.1005-0264.2017.01.006.
[14]	ZHANG T, DONG SJ, HAN YJ. Application of fat attenuation parameter to the diagnosis of fatty liver of different Chinese medicine syndromes[J]. Henan Tradit Chin Med, 2016, 36(11): 1940-1942. DOI: 10.16367/j.issn.1003-5028.2016.11.0780. 张婷, 董淑娟, 韩艳俊. 脂肪衰减参数在不同中医证型脂肪肝诊断中的应用[J]. 河南中医, 2016, 36(11): 1940-1942. DOI: 10.16367/j.issn.1003-5028.2016.11.0780.
[15]	LI ZJ, WU PC, ZHOU S. Effect observation on treating nonalcoholic fatty liver with Tiaogan Yunpi Huazhuo decoction and electroacupuncture[J]. J Changchun Univ Chin Med, 2021, 37(1): 103-107. DOI: 10.13463/j.cnki.cczyy.2021.01.028. 李枝锦, 吴平财, 周山. 调肝运脾化浊方联合电针治疗非酒精性脂肪肝[J]. 长春中医药大学学报, 2021, 37(1): 103-107. DOI: 10.13463/j.cnki.cczyy.2021.01.028.
[16]	ZHANG XL, LIU MJ. Study on optimum scheme of establishing rat obesity model based on modern literature[J]. J Changchun Univ Chin Med, 2019, 35(1): 131-135. DOI: 10.13463/j.cnki.cczyy.2019.01.039. 张晓林, 刘明军. 基于现代文献探索大鼠肥胖模型建立的优选方案研究[J]. 长春中医药大学学报, 2019, 35(1): 131-135. DOI: 10.13463/j.cnki.cczyy.2019.01.039.
[17]	ZHU YB, WANG Q, WU CY, et al. Logistic regression analysis on relationships between traditional Chinese medicine constitutional types and overweight or obesity[J]. J Chin Integr Med, 2010, 8(11): 1023-1028. DOI: 10.3736/jcim20101104. 朱燕波, 王琦, 吴承玉, 等. 18805例中国成年人中医体质类型与超重和肥胖关系的Logistic回归分析[J]. 中西医结合学报, 2010, 8(11): 1023-1028. DOI: 10.3736/jcim20101104.